Systemic Toll of Hearing Loss Extends Far Beyond Ears, Exposing Gaps in Care Access as Regenerative Therapies Near

The New Scientist account correctly flags observational ties between sensorineural hearing loss and dementia, cardiovascular events, and mortality, yet underplays how most supporting data derive from large cohort studies rather than randomized trials, leaving residual confounding by socioeconomic status and vascular risk factors unaddressed. A 2020 Lancet Commission meta-analysis of 28 studies (n>1 million) identified mid-life hearing loss as the largest modifiable dementia risk factor, but relied on self-report or pure-tone thresholds without longitudinal audiometric follow-up, limiting causal claims. Parallel work in the Journal of the American College of Cardiology has linked moderate loss to incident myocardial infarction via shared microvascular pathways, yet sample sizes remain modest and noise-exposure histories often incomplete. The WHO 2021 World Report on Hearing, drawing on global burden modeling rather than primary data collection, projects 2.5 billion affected by 2050 but notes severe under-provision of services in low-income regions, a dimension the original piece only touches. Emerging gene and small-molecule therapies targeting hair-cell regeneration show promise in early-phase trials, yet regulatory and reimbursement debates will decide whether these reach the 700 million who may need intervention, especially where stigma and device costs already suppress uptake. Missed in coverage is the feedback loop: untreated loss accelerates social withdrawal that itself worsens cardiovascular and cognitive trajectories, underscoring why access reforms must precede pharmacological breakthroughs.